Capecitabine combined with oxaliplatin (CapOx) in clinical practice: How significant is peripheral neuropathy?

Abstract

Background: There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m2, day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m2, day 1, every 14 days). We aimed to determine PN incidence and associations during CapOx, and 6 and 12 months after CapOx. Patients and methods: Retrospective audit of 188 oxaliplatin-naive colorectal cancer patients (87 adjuvant, 101 palliative) who received at least one cycle of CapOx. Neurosensory Common Toxicity Criteria Adverse Events version 3 were applied. Results: Overall, 94% experienced acute PN. Worst severities for adjuvant and palliative patients, respectively, wer..